Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|March 25, 2025

Reliance on Traditional Research Methods

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, talks traditional research methods in clinical trials and why industry leaders remain reliant on them.

In a recent video interview with Applied Clinical Trials, Rachael Higgins, chief commercial officer, PicnicHealth, discussed the company’s recently released 2025 Annual State of Observational Research Report. She highlighted some of the key findings including the persistence of more traditional research methods as well as how patient retention and incomplete data are creating challenges for the industry.

ACT: Why do you think so many industry leaders are still reliant on more traditional research methods?

Higgins: I think about this all the time. I think this is probably the number one thing that people in my space think about. I think it's just comfort. I think people are comfortable with what they know, right? While the industry has mounting pressures to do things differently, and they know this, it's kind of like the devil you know, right? Even though they find they're spending way more money than they need to, things are taking way too long, they're not retaining patients, they’re certainly not getting the data that they need, they're like, “Well, we know this. It's tried and true, so we're more comfortable doing that.” That being said, as we mentioned those stats before, 78% of the folks that we actually interviewed are definitely open to doing things in other ways. I think it's just going to have to be continually talking to them, educating them, explaining to them that while it is different, different doesn't necessarily mean scary, and it could certainly be advantageous for them in the end.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
© putilov_denis - © putilov_denis - stock.adobe.com
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.